Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

SENTI-202

Cell therapy (CAR-NK) · Kills target cells, directed at CD33, FLT3 and endomucin (EMCN) · developed by Senti Biosciences

Phase 1 Most advanced trial

SNTI Developer

1 Registered trials

What is SENTI-202?

SENTI-202 is an off-the-shelf engineered NK cell therapy expressing a logic-gated CAR targeting CD33 and/or FLT3, an inhibitory CAR recognizing endomucin to spare healthy cells, and calibrated IL-15 for enhanced persistence and killing. It is being studied in acute myeloid leukemia, myelodysplastic syndrome, and other CD33/FLT3-expressing hematological malignancies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Fludarabine, Cytarabine (ara-C)
Drug type: Cell therapy (CAR-NK)
Targets: CD33 (antigen), FLT3 (antigen), endomucin (EMCN) (antigen)
Mechanism: Kills target cells, directed at CD33, FLT3 and endomucin (EMCN)
Pathways: IL-15 receptor signaling
Therapy area: Oncology
Developer: Senti Biosciences (SNTI)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06325748	Phase 1	AML/MDS	Active not recruiting	SNTI

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AML/MDSCD33 Expressing Hematological MalignanciesFLT3 Expressing Hematological Malignancies

Other drugs acting on CD33 / FLT3 / EMCN

Gilteritinib FDA approved Midostaurin FDA approved Pexidartinib FDA approved Actinium Ac 225 Lintuzumab Phase 1 BI 836858 Phase 2/3 BMF-500 Phase 1 CDX-301 Phase 2 CLN-049 Phase 1 Dapolsertib Phase 1/2 Lintuzumab Phase 1 Lintuzumab-Ac225 Phase 1/2 Lomonitinib Phase 2/3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the SNTI page.

Follow SNTI, the company behind SENTI-202

See SNTI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SNTI catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z